# **PROVIDER BULLETIN** PROVIDER INFORMATION



July 1, 2021

# Updated Minnesota Health Care Programs and SecureBlue Prior Authorization and Medical Policy Requirements

Effective September 1, 2021, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) will be updating its government programs medical policy and preauthorization/precertification/notification lists. The lists clarify medical policy, prior authorization, and notification requirements for the Minnesota Health Care Programs (Families and Children, MinnesotaCare, and Minnesota Senior Care Plus) and SecureBlue<sup>SM</sup> (MSHO) products.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring they receive appropriate, quality care while also maintaining overall costs. The prior authorization process ensures that the health service or drug being proposed is medically necessary, and reflective of evidence-based medicine and industry standards, prior to treatment. This process helps us manage the cost and quality of care appropriately for our members.

| Policy #    | Policy Name  | New Policy | Prior Authorization<br>Required |      |
|-------------|--|------------|---------------------------------|------|
| -           |  | -          | Medicaid                        | MSHO |
| CG-LAB-17   | Molecular Gastrointestinal Pathogen Panel<br>(GIPP) Testing for Infectious Diarrhea in the<br>Outpatient Setting |            |                                 | No   |
| GENE.00056  | Gene Expression Profiling for Bladder Cancer   | Yes        | No                              | No   |
| LAB.00038   | Cell-free DNA Testing to Aid in the Monitoring of Kidney Transplants for Rejection                               | Yes        | No                              | No   |
| LAB.00039   | Pooled Antibiotic Sensitivity Testing  | Yes        | No                              | No   |
| SURG.00159  | Focal Laser Ablation for the Treatment of Prostate Cancer  | Yes        | No                              | No   |
| ING-CC-0186 | Margenza (margetuximab-cmkb)   | Yes        | Yes                             | Yes  |
| ING-CC-0189 | Amondys 45 (casimersen)  | Yes        | Yes                             | Yes  |
| ING-CC-0187 | Breyanzi (lisocabtagene maraleucel)  | Yes        | Yes                             | Yes  |
| ING-CC-0190 | Nulibry (fosdenopterin)  | Yes        | Yes                             | Yes  |

The following **new** policies and/or prior authorization requirements **will be applicable** to subscriber claims on or after **September 1, 2021**.

| Policy #    | Policy Name New Policy  |                        | Prior Authorization<br>Required |      |
|-------------|---|------------------------|---------------------------------|------|
|             |   |                        | Medicaid                        | MSHO |
| ING-CC-0191 | Pepaxto (melphalan flufenamide; melflufen)  | Yes                    | Yes                             | Yes  |
| ING-CC-0192 | Cosela (trilaciclib)  | Yes                    | Yes                             | Yes  |
| ING-CC-0193 | Evkeeza (evinacumab)  | Yes                    | Yes                             | Yes  |
| ING-CC-0194 | Cabenuva (cabotegravir extended-release;<br>rilpivirine extended-release) Injection | Yes<br>(Medicaid only) | Yes                             | No   |

The following policies have transitioned to new policy numbers, with changes in clinical criteria, and **will be applicable** to subscriber claims on or after **September 1, 2021**.

| New Policy # | Prior Policy             | Policy Name   | Prior Auth<br>Requ |      |
|--------------|--------------------------|---|--------------------|------|
|              | #                        |   | Medicaid           | MSHO |
| МНСР         | ING-CC-0179              | Blenrep (belantamab mafodotin-blmf)                 | Yes                | Yes  |
| МНСР         | ING-CC-0180              | Monjuvi (tafasitamab)                               | Yes                | Yes  |
| МНСР         | ING-CC-0169              | Phesgo (pertuzumab, trastuzumab, and hyaluronidase) | Yes                | Yes  |
| МНСР         | ING-CC-0172              | Viltepso (viltolarsen)                              | Yes                | Yes  |
| МНСР         | ING-CC-0171              | Zepzelca (lurbinectedin)                            | Yes                | Yes  |
| CG-SURG-110  | SURG.00022               | Lung Volume Reduction Surgery                       | Yes                | Yes  |
| CG-GENE-23   | GENE.00007<br>GENE.00017 | Genetic Testing for Heritable Cardiac<br>Conditions | Yes                | Yes  |
| CG-GENE-13   | CG-GENE-05               | Genetic Testing for Inherited Diseases              | Yes                | Yes  |

The following policies have changes in clinical criteria and **will be applicable** to subscriber claims on or after **September 1, 2021**.

| Policy #   | Policy Name   |          | orization<br>ired |
|------------|---|----------|-------------------|
|            |   | Medicaid | MSHO              |
| ANC.00008  | Cosmetic and Reconstructive Services of the Head and Neck                             | Yes      | Yes               |
| CG-ANC-08  | Mobile Device-Based Health Management Applications                                    | No       | No                |
| CG-MED-68  | Therapeutic Apheresis   | No       | No                |
| CG-MED-87  | Single Photon Emission Computed Tomography Scans for<br>Noncardiovascular Indications | Yes      | Yes               |
| CG-SURG-18 | Septoplasty   | Yes      | Yes               |
| CG-SURG-55 | Intracardiac Electrophysiological Studies (EPS) and Catheter Ablation                 | Yes      | Yes               |
| CG-SURG-71 | Reduction Mammoplasty   | Yes      | Yes               |

| Policy #    | Policy Name   | Prior Auth<br>Requ |      |
|-------------|---|--------------------|------|
| i oncy "    | Toney Func  | Medicaid           | MSHO |
| CG-SURG-78  | Locoregional and Surgical Techniques for Treating Primary and<br>Metastatic Liver Malignancies  | Yes                | Yes  |
| CG-SURG-82  | Bone-Anchored and Bone Conduction Hearing Aids  | Yes                | Yes  |
| CG-SURG-88  | Mastectomy for Gynecomastia   | Yes                | Yes  |
| CG-SURG-95  | Sacral Nerve Stimulation and Percutaneous Tibial Nerve<br>Stimulation for Urinary and Fecal Incontinence, Urinary<br>Retention                  | Yes                | Yes  |
| CG-SURG-97  | Cardioverter Defibrillators   | Yes                | Yes  |
| CG-SURG-107 | Surgical and Minimally Invasive Treatments for Benign Prostatic<br>Hyperplasia (BPH)  | Yes                | Yes  |
| DME.00041   | Low Intensity Therapeutic Ultrasound  | No                 | No   |
| GENE.00049  | Circulating Tumor DNA Panel Testing for Cancer (Liquid Biopsy)  | No                 | No   |
| LAB.00003   | In Vitro Chemosensitivity Assays and In Vitro Chemoresistance<br>Assays   | No                 | No   |
| LAB.00015   | Detection of Circulating Tumor Cells  | No                 | No   |
| LAB.00033   | Protein Biomarkers for the Screening, Detection and<br>Management of Prostate Cancer  |                    | No   |
| MED.00087   | 0087 Optical Detection for Screening and Identification of Cervical<br>Cancer   |                    | No   |
| SURG.00121  | Transcatheter Heart Valve Procedures (TAVR and TPVI only)   | Yes                | Yes  |
| SURG.00145  | RG.00145Mechanical Circulatory Assist Devices (Ventricular Assist<br>Devices, Percutaneous Ventricular Assist Devices and Artificial<br>Hearts) |                    | Yes  |
| TRANS.00016 | Umbilical Cord Blood Progenitor Cell Collection, Storage and Transplantation  | Yes                | Yes  |
| ING-CC-0140 | Zulresso (brexanolone)  | Yes                | Yes  |
| ING-CC-0019 | Zoledronic Acid Agents  | Yes                | Yes  |
| ING-CC-0099 | Abraxane (paclitaxel, protein bound)  | Yes                | Yes  |
| ING-CC-0094 | Pemetrexed Agents (Alimta, Pemfexy)   | Yes                | Yes  |
| ING-CC-0130 | Imfinzi (durvalumab)  | Yes                | Yes  |
| ING-CC-0118 | Radioimmunotherapy and Somatostatin Recentor Targeted   |                    | Yes  |
| ING-CC-0112 | Xofigo (Radium Ra 223 Dichloride)   | Yes                | Yes  |
| ING-CC-0123 | Cyramza (ramucirumab)   | Yes                | Yes  |
| ING-CC-0122 | Arzerra (ofatumumab)  | Yes                | Yes  |

| Policy #    | Policy Name   |          | Prior Authorization<br>Required |  |
|-------------|---|----------|---------------------------------|--|
| - ••y       |   | Medicaid | MSHO                            |  |
| ING-CC-0120 | Kyprolis (carfilzomib)  | Yes      | Yes                             |  |
| ING-CC-0090 | Ixempra (ixabepilone)   | Yes      | Yes                             |  |
| ING-CC-0110 | Perjeta (pertuzumab)  | Yes      | Yes                             |  |
| ING-CC-0115 | Kadcyla (ado-trastuzumab)   | Yes      | Yes                             |  |
| ING-CC-0108 | Halaven (eribulin)  | Yes      | Yes                             |  |
| ING-CC-0067 | Prostacyclin Infusion and Inhalation Therapy  | Yes      | Yes                             |  |
| ING-CC-0075 | Rituximab Agents for Non-Oncologic Indications  | Yes      | Yes                             |  |
| ING-CC-0177 | Zilretta (triamcinolone acetonide extended-release)   | Yes      | Yes                             |  |
| ING-CC-0159 | Scenesse (afamelanotide)  | Yes      | Yes                             |  |
| ING-CC-0151 | Yescarta (axicabtagene ciloleucel)  | Yes      | Yes                             |  |
| AI-03       | Advanced Oncologic ImagingYes• PET Imaging for Oncologic Indications  |          | Yes                             |  |
| AI-05       | <ul> <li>Advanced Imaging of the Heart</li> <li>Cardiac CT with Quantitative Evaluation of Coronary<br/>Calcification</li> <li>Cardiac MRI</li> <li>Myocardial Perfusion Imaging</li> <li>Cardiac Blood Pool Imaging</li> </ul> | Yes      | Yes                             |  |

The following prior authorization requirements will be removed and **will not be applicable** under the medical benefit plan to subscriber claims on or after **September 1, 2021**. However, the policies will remain in effect.

| Policy #  |                        |     | Prior Authorization<br>Required |  |
|-----------|------------------------|-----|---------------------------------|--|
| ·         |                        |     | MSHO                            |  |
| MED.00085 | Antineoplaston Therapy | Yes | Yes                             |  |

The following policies and/or prior authorization requirements will be archived and **will not be applicable** under the medical benefit plan to subscriber claims on or after **September 1, 2021**.

| Policy #   | Policy Name                                     |          | Prior Authorization<br>Required |  |
|------------|---|----------|---------------------------------|--|
| •          |   | Medicaid | MSHO                            |  |
| CG-MED-88  | Preimplantation Genetic Diagnosis Testing       | No       | No                              |  |
| CG-GENE-20 | Epidermal Growth Factor Receptor (EFGR) Testing | No       | No                              |  |
| MED.00077  | In-Vivo Analysis of Gastrointestinal Lesions    | Yes      | Yes                             |  |
| МНСР       | Portrazza (necitumumab)                         | Yes      | Yes                             |  |

#### MCG Care Guidelines 25th Edition

Effective **September 1, 2021**, Amerigroup is upgrading to the 25th edition of MCG Care Guidelines for the following modules: Inpatient & Surgical Care (ISC), General Recovery Care (GRC), Chronic Care (CC),

Recovery Facility Care (RFC), and Behavioral Health Care (BHC). The below tables highlight new guidelines and changes that may be considered more restrictive.

| Guideline  | MCG<br>Code | 24 <sup>th</sup> Edition GLOS     | 25 <sup>th</sup> Edition GLOS      |
|--|-------------|-----------------------------------|------------------------------------|
| Aortic Coarctation, Angioplasty  | S-152       | Ambulatory or 1 day postoperative | Ambulatory                         |
| Cardiac Septal Defect: Atrial, Transcatheter Closure                       | W0016       | Ambulatory or 1 day postoperative | Ambulatory                         |
| Esophageal Diverticulectomy, Endoscopic                                    | S-445       | Ambulatory or 1 day postoperative | Ambulatory                         |
| Gastrectomy, Partial - Billroth I or II                                    | S-510       | 4 or 6 days postoperative         | 5 days postoperative               |
| Hernia Repair (Non-Hiatal)   | S-1305      | Ambulatory or 1 day postoperative | Ambulatory                         |
| Pancreatectomy   | S-1200      | 5 or 7 days postoperative         | 6 days postoperative               |
| Pyloroplasty and Vagotomy  | S-990       | 4 or 6 days postoperative         | 4 days postoperative               |
| Cervical Laminectomy   | W0097       | 2 days postoperative              | Ambulatory or 2 days postoperative |
| Lumbar Diskectomy, Foraminotomy, or<br>Laminotomy                          | W0091       | Ambulatory or 1 day postoperative | Ambulatory                         |
| Removal of Posterior Spinal Instrumentation                                | S-530       | 1 day postoperative               | Ambulatory or 1 day postoperative  |
| Shoulder Hemiarthroplasty  | W0138       | 1 day postoperative               | Ambulatory or 1 day postoperative  |
| Spine, Scoliosis, Posterior Instrumentation,<br>Pediatric                  | W0156       | 4 days postoperative              | 3 days postoperative               |
| Bladder Resection: Cystectomy with Urinary Diversion, Conduit or Continent | S-190       | 5 or 6 days postoperative         | 5 days postoperative               |
| Prostatectomy, Transurethral Resection<br>(TURP)                           | S-970       | Ambulatory or 1 day postoperative | Ambulatory                         |
| Urethroplasty  | S-1172      | Ambulatory or 1 day postoperative | Ambulatory                         |

Goal Length of Stay (GLOS) for Inpatient & Surgical Care (ISC)

#### New Guidelines for Behavioral Health Care (BHC) and Recovery Facility Care (RFC)

| Body System           | Guideline Title  | MCG - Code |
|-----------------------|--|------------|
| Withdrawal Management | Withdrawal Management, Adult: Inpatient Care               | B-031-IP   |
| Withdrawal Management | Withdrawal Management, Adult: Intensive Outpatient Program | B-031-IOP  |
| Withdrawal Management | Withdrawal Management, Adult: Outpatient Care              | B-031-AOP  |
| Withdrawal Management | Withdrawal Management, Adult: Partial Hospital Program     | B-031-PHP  |
| Withdrawal Management | Withdrawal Management, Adult: Residential Care             | B-031-RES  |
| Cardiology            | Hypertension   | M-5197     |
| Cardiology            | Peripheral Vascular Disease (PVD)                          | M-7087     |
| Nephrology            | Rhabdomyolysis   | M-7095     |
| Nephrology            | Encephalopathy   | M-7100     |

| Body System      | Guideline Title | MCG - Code |
|------------------|-----------------|------------|
| Thoracic Surgery | Rib Fracture    | M-5545     |

#### Customizations to MCG Care Guideline 25th Edition

Effective September 1, 2021, the following MCG care guideline 25th edition customization will be implemented:

 Transcranial Magnetic Stimulation, W0174 (previously ORG: B-801-T) - Revised Clinical Indications for Procedure

To view a detailed summary of customizations click on this **link**.

For questions, please contact the provider service number on the back of the member's ID card.

## Where do I find the current government programs Precertification/Preauthorization/Notification list?

Go to https://provider.publicprograms.bluecrossmn.com/minnesota-provider/resources/prior-authorization

# OR

#### Go to providers.bluecrossmn.com

- Under Tools & Resources, select Minnesota Health Care Programs site
- Under *Resources*, select **Prior Authorization Requirements** and scroll down to *Related Information* to select **Prior Authorization Grid**

## Where do I find the current government programs Medical Policy Grid?

Go to https://provider.publicprograms.bluecrossmn.com/minnesota-provider/resources/provider-manualsand-guides

• Select Medical Policies and UM Guidelines

#### OR

#### Go to providers.bluecrossmn.com

- Under Tools & Resources, select Minnesota Health Care Programs site
- Under Resources, select Manuals and Guides
- Click on Medical Policies and UM Guidelines

#### Where can I access medical policies?

• Minnesota Department of Health Services (MHCP) policies:

http://www.dhs.state.mn.us/main/idcplg?IdcService=GET\_DYNAMIC\_CONVERSION&RevisionSelecti onMethod=LatestReleased&dDocName=dhs16\_157386

• Blue Cross policies:

https://www.bluecrossmn.com/providers/medical-policy-and-utilization-management

• Amerigroup policies:

https://provider.publicprograms.bluecrossmn.com/minnesota-provider/medical-policies-and-clinical-guidelines

AND

#### https://www.anthem.com/pharmacyinformation/clinicalcriteria

Please note that the Precertification Lookup Tool is not available for Prior Authorization Lookup.

Questions? If you have questions, please contact Blue Cross Provider Services at 1-866-518-8448.